We use cookies and other tools to enhance your experience on our website and to analyze our web traffic.
For more information about these cookies and the data collected, please refer to our
Privacy Policy.
5.9.0 Exclusion Criteria at NP Testing at Baseline Assessment
DAS-II Summary IQ
Automatic stop measure: DAS-II Summary IQ = 55 (if during testing the child’s
performance appears poor, be sure DAS-II is scored within 48 hours)
Complete Neuropsychological Abnormal Test Log (NPAB)
DAS-II Exclusion criteria at Baseline Assessment
If at all possible, information should be given to the Coordinator related to the
performance of the child on the DAS-II concerning the = 55 cut-off prior to the
family leaving after baseline NP testing, so that randomization can take place
so that they can inform the coordinator if the child looks like they may be scoring
in the neighborhood of the cut-off. Most likely, this will involve the examiner
having to drop below most all expected item sets.
In case it is not possible to specifically determine the child will have a GCA > 55,
a maximum of 48 hours is allowed for formal scoring prior to randomization.
Stop/Safety Change Measure
For cases wherein the child scores 55 > GCA < 70, a written protocol needs to
be established at each site, consistent with IRB, for who will contact the family
and give timely feedback.
After feedback is given, check the appropriate boxes on Administrative Form
(NPAB) related to the status of Follow-Up procedures for the child (i.e., “Parent
Informed?”, “Site PI Informed?”, “DCC Informed?”, “Follow-UP?”)
5.9.1 Stop/Safety Change Measure
If NP testing reveals a DAS-II summary score of = 69 (summary IQ)
The parent/guardian will be notified and the participant will be referred to his
primary physician.
A medical referral form (MRF) must be completed
DAS-II Overall IQ decline of 1.5 SD during follow up assessment
Complete Neuropsychological Abnormal Test Log (NPAB)
5.9.2 Feedback to Parents
Feedback to parents will be handled on a site-specific basis in accordance with clinical
and IRB policies